Bisfosfonaat (Dutch Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bisfosfonaat" in Dutch language version.

refsWebsite

Global rank Dutch rank

9nih.gov

4^th place

12^th place

8doi.org

2^nd place

8^th place

2archive.org

6^th place

25^th place

1web.archive.org

1^st place

1ama-assn.org

3,257^th place

1,970^th place

ama-assn.org

archinte.ama-assn.org

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (April 2008). Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med. 168 (8): 826–31. PMID 18443257. DOI: 10.1001/archinte.168.8.826.

archive.org

van Beek E, Cohen L, Leroy I, Ebetino F, Löwik C, Papapoulos S (November 2003). Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33 (5): 805–11. PMID 14623056. DOI: 10.1016/j.bone.2003.07.007.
Cummings SR, Schwartz AV, Black DM (May 2007). Alendronate and atrial fibrillation. N. Engl. J. Med. 356 (18): 1895–6. PMID 17476024. DOI: 10.1056/NEJMc076132.

doi.org

Fleisch H (2002). Development of bisphosphonates. Breast Cancer Res 4 (1): 30–4. PMID 11879557. DOI: 10.1186/bcr414.
Frith J, Mönkkönen J, Blackburn G, Russell R, Rogers M (1997). Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12 (9): 1358–67. PMID 9286751. DOI: 10.1359/jbmr.1997.12.9.1358.
van Beek E, Cohen L, Leroy I, Ebetino F, Löwik C, Papapoulos S (November 2003). Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33 (5): 805–11. PMID 14623056. DOI: 10.1016/j.bone.2003.07.007.
van beek E, Löwik C, van der Pluijm G, Papapoulos S (1999). The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14 (5): 722–9. PMID 10320520. DOI: 10.1359/jbmr.1999.14.5.722.
Wysowski D, Chang J (2005). Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 165 (3): 346–7. PMID 15710802. DOI: 10.1001/archinte.165.3.346-b.
Black DM, Delmas PD, Eastell R, et al (May 2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 (18): 1809–22. PMID 17476007. DOI: 10.1056/NEJMoa067312. Gearchiveerd van origineel op 5 januari 2010. Geraadpleegd op 5 juni 2023.
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (April 2008). Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med. 168 (8): 826–31. PMID 18443257. DOI: 10.1001/archinte.168.8.826.
Cummings SR, Schwartz AV, Black DM (May 2007). Alendronate and atrial fibrillation. N. Engl. J. Med. 356 (18): 1895–6. PMID 17476024. DOI: 10.1056/NEJMc076132.

nih.gov

ncbi.nlm.nih.gov

Fleisch H (2002). Development of bisphosphonates. Breast Cancer Res 4 (1): 30–4. PMID 11879557. DOI: 10.1186/bcr414.
Frith J, Mönkkönen J, Blackburn G, Russell R, Rogers M (1997). Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12 (9): 1358–67. PMID 9286751. DOI: 10.1359/jbmr.1997.12.9.1358.
van Beek E, Cohen L, Leroy I, Ebetino F, Löwik C, Papapoulos S (November 2003). Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33 (5): 805–11. PMID 14623056. DOI: 10.1016/j.bone.2003.07.007.
van beek E, Löwik C, van der Pluijm G, Papapoulos S (1999). The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14 (5): 722–9. PMID 10320520. DOI: 10.1359/jbmr.1999.14.5.722.
Woo S, Hellstein J, Kalmar J (2006). Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (10): 753–61. PMID 16702591.
Wysowski D, Chang J (2005). Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 165 (3): 346–7. PMID 15710802. DOI: 10.1001/archinte.165.3.346-b.
Black DM, Delmas PD, Eastell R, et al (May 2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 (18): 1809–22. PMID 17476007. DOI: 10.1056/NEJMoa067312. Gearchiveerd van origineel op 5 januari 2010. Geraadpleegd op 5 juni 2023.
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (April 2008). Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med. 168 (8): 826–31. PMID 18443257. DOI: 10.1001/archinte.168.8.826.
Cummings SR, Schwartz AV, Black DM (May 2007). Alendronate and atrial fibrillation. N. Engl. J. Med. 356 (18): 1895–6. PMID 17476024. DOI: 10.1056/NEJMc076132.

web.archive.org

Black DM, Delmas PD, Eastell R, et al (May 2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 (18): 1809–22. PMID 17476007. DOI: 10.1056/NEJMoa067312. Gearchiveerd van origineel op 5 januari 2010. Geraadpleegd op 5 juni 2023.